1. ESMO Open. 2017 Jun 21;2(2):e000173. doi: 10.1136/esmoopen-2017-000173. 
eCollection 2017.

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in 
patients with metastatic melanoma treated with a BRAF inhibitor.

Louveau B(1), Tost J(2), Mauger F(2), Sadoux A(1), Podgorniak MP(1), How-Kit 
A(3), Pages C(4), Roux J(4), Da Meda L(4), Lebbe C(4)(5)(6), Mourah S(1)(5)(6).

Author information:
(1)Assistance Publique-Hôpitaux de Paris, Laboratoire de Pharmacogénomique, 
Hôpital Saint-Louis, Paris, France.
(2)Laboratory for Epigenetics and Environment, Centre National de Génotypage, 
CEA-Institut de Génomique, Evry, France.
(3)Laboratory for Genomics, Fondation Jean Dausset-CEPH, Paris, France.
(4)Département de Dermatologie, Assistance publique-Hôpitaux de Paris, Paris, 
France.
(5)Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
(6)UMR-976, INSERM, Hôpital Saint-Louis, Paris, France.

Comment in
    ESMO Open. 2017 Jul 19;2(3):e000207. doi: 10.1136/esmoopen-2017-000207.

DOI: 10.1136/esmoopen-2017-000173
PMCID: PMC5519801
PMID: 28761746

Conflict of interest statement: Competing interests: CL declares honoraria from 
Roche, advisory roles at Roche, GSK, Novartis, BMS, MSD and Amgen, and travel 
accommodation provided by Roche. SM declares a consulting role at Roche and 
Novartis.